Cargando…
LightUp(®) probes in clinical diagnostics
The LightUp(®) Probe technology has now matured and reached the phase where it has been implemented in commercial reagent kits, i.e. the ReSSQ(®) product line. Several properties of the LightUp(®) probes make them particularly suitable for clinical settings. For instance, extraordinary shelf life an...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112358/ https://www.ncbi.nlm.nih.gov/pubmed/16466783 http://dx.doi.org/10.1016/j.mam.2005.12.005 |
_version_ | 1783513464422006784 |
---|---|
author | Leijon, Mikael Mousavi-Jazi, Mehrdad Kubista, Mikael |
author_facet | Leijon, Mikael Mousavi-Jazi, Mehrdad Kubista, Mikael |
author_sort | Leijon, Mikael |
collection | PubMed |
description | The LightUp(®) Probe technology has now matured and reached the phase where it has been implemented in commercial reagent kits, i.e. the ReSSQ(®) product line. Several properties of the LightUp(®) probes make them particularly suitable for clinical settings. For instance, extraordinary shelf life and a chemical stability that allows convenient fridge storage. The origin of the higher stability of LightUp(®) probe kits compared to others, based on alternative probe technologies, is partly the relatively good stability of cyanine dyes but also the resistance towards nucleases and proteases of the synthetic DNA analogue peptide nucleic acid that is used as the sequence recognizing element in LightUp probes. It is clear from recent trends in the PCR amplification hardware technology that the instrumentation is becoming more flexible and less adapted for dedicated probe chemistries. This will pave the way for increased standardization in the field of DNA diagnostics and the development of cross-platform assays. In the present review the LightUp technology will briefly be presented and discussed. The utility of the technology will be illustrated by examples from cytomegalovirus quantification and monitoring of the viral load of the SARS Coronavirus. An example of cancer diagnostics by detection of altered gene expression patterns will also be shown. |
format | Online Article Text |
id | pubmed-7112358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71123582020-04-02 LightUp(®) probes in clinical diagnostics Leijon, Mikael Mousavi-Jazi, Mehrdad Kubista, Mikael Mol Aspects Med Article The LightUp(®) Probe technology has now matured and reached the phase where it has been implemented in commercial reagent kits, i.e. the ReSSQ(®) product line. Several properties of the LightUp(®) probes make them particularly suitable for clinical settings. For instance, extraordinary shelf life and a chemical stability that allows convenient fridge storage. The origin of the higher stability of LightUp(®) probe kits compared to others, based on alternative probe technologies, is partly the relatively good stability of cyanine dyes but also the resistance towards nucleases and proteases of the synthetic DNA analogue peptide nucleic acid that is used as the sequence recognizing element in LightUp probes. It is clear from recent trends in the PCR amplification hardware technology that the instrumentation is becoming more flexible and less adapted for dedicated probe chemistries. This will pave the way for increased standardization in the field of DNA diagnostics and the development of cross-platform assays. In the present review the LightUp technology will briefly be presented and discussed. The utility of the technology will be illustrated by examples from cytomegalovirus quantification and monitoring of the viral load of the SARS Coronavirus. An example of cancer diagnostics by detection of altered gene expression patterns will also be shown. Elsevier Ltd. 2006 2006-02-08 /pmc/articles/PMC7112358/ /pubmed/16466783 http://dx.doi.org/10.1016/j.mam.2005.12.005 Text en Copyright © 2006 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Leijon, Mikael Mousavi-Jazi, Mehrdad Kubista, Mikael LightUp(®) probes in clinical diagnostics |
title | LightUp(®) probes in clinical diagnostics |
title_full | LightUp(®) probes in clinical diagnostics |
title_fullStr | LightUp(®) probes in clinical diagnostics |
title_full_unstemmed | LightUp(®) probes in clinical diagnostics |
title_short | LightUp(®) probes in clinical diagnostics |
title_sort | lightup(®) probes in clinical diagnostics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112358/ https://www.ncbi.nlm.nih.gov/pubmed/16466783 http://dx.doi.org/10.1016/j.mam.2005.12.005 |
work_keys_str_mv | AT leijonmikael lightupprobesinclinicaldiagnostics AT mousavijazimehrdad lightupprobesinclinicaldiagnostics AT kubistamikael lightupprobesinclinicaldiagnostics |